Decade-long use of the antimicrobial peptide combination tyrothricin does not pose a major risk of acquired resistance with gram-positive bacteria and candida spp

Pharmazie

Volumn 69, Issue 11, 2014, Pages 838-841

  Stauss Grabo, M ^a,d   Atiye, S ^b,d   Le, T ^b,d   Kretschmar, M ^c,d  

^a UNIVERSITY OF APPLIED SCIENCES   (Germany)

^b Engelhard Arzneimittel GmbH and Co KG2   (Germany)

^c MVZ Community Laboratory Suhl   (Germany)

^d TECHNISCHE HOCHSCHULE MITTELHESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

POLYPEPTIDE ANTIBIOTIC AGENT; TYROTHRICIN; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; ASSAY; BACTERIUM ISOLATE; CANDIDA; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CORYNEBACTERIUM; DRUG INHIBITION; ENTEROCOCCUS FAECALIS; FUNGUS ISOLATION; GRAM POSITIVE BACTERIUM; HOSPITAL PATIENT; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MICRODILUTION ASSAY; MINIMUM INHIBITORY CONCENTRATION; MUCOSA; NONHUMAN; OUTPATIENT; RISK ASSESSMENT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS HAEMOLYTICUS; STREPTOCOCCUS PYOGENES; BACTERIAL INFECTION; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOSIS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CANDIDA; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, FUNGAL; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; TYROTHRICIN;

EID: 84920851400     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2014.4686     Document Type: Article

References (30)

1. Baker PJ, Evans RT, Slots J, Gen RJ (1985) Susceptibility of human oral anaerobic bacteria to antibiotics suitable for topical use. J Clin Periodontol 12: 201-208.
2. Bayerl C, Völp A (2004) Tyrothricin powder in the treatment of cutaneous lesions. Pharmazie 59: 864-868.
3. Bourinbaiar AS, Krasinski K, Borkowsky W (1994) Anti-HIV effect of gramicidin in vitro: potential for spermicide use. Life Sci 54: 5-9.
4. Bradshaw J (2003) Cationic antimicrobial peptides: issues for potential clinical use. BioDrugs 17: 233-240.
5. DIN-Taschenbuch 222 (2004) Medizinische Mikrobiologie und Immunologie. Diagnostische Verfahren, ed 4, Berlin/Cologne, Beuth
6. Dubos RJ (1939) Studies on a bactericidal agent extracted from a soil bacillus. J Exp Med 70: 249-256. Cited from Tang XU, Thibault, Boyd
7. RK (1992) Characterisation of the tyrothricin and gramicidin fractions of the tyrothricin complex from Bacillus brevis using liquid chromatography and mass spectrometry. Int J Mass Spectroscop Ion Proc 122: 153-179.
8. Florestano HJ, Bahler ME, Richards AB (1956) Effect of actamer and tyrothricin on oral microorganisms. J Am Pharm Assoc 45: 13-16. Cited from Ruckdeschel et al. (1983).
9. Franklin TJ, Snow GA (eds). (1988) Biochemistry of antimicrobial action. New York (USA), Chapman & Hall, p. 61-64.
10. Grossgebauer K, HartmannD(1978) Antiviral activity of tyrothricin against Sendai virus in suspension tests. Zentralbl Bakteriol OrigB166: 434-442.
11. Hancock RE; Patrzykat A (2002) Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr Drug Targets Infect Disord 2: 79-83.
12. Hartmann D, Grossgebauer K (1979) Schutzversuche mit Tyrothricin an der Herpes-simplex-Virus-infizierten Maus. Arzneimittelforschung 29: 50-54.
13. Khandelia H, Ipsen JH, Mouritsen OG (2008) The impact of peptides on lipid membranes. Biochim Biophys Acta 1778: 528-536.
14. Kretschmar M, Nichterlein T, Hof H, Burger KJ (1995) Tyrothricin. BakterizideWirkung auf fakultativ pathogene grampositive aerobe Bakterien der Mundflora und MRSA. Chemotherapie J 4: 156-159.
15. Kretschmar M, Witte W, Hof H (1996a) Bacterial activity of tyrothricin against methicillin resistant Staphylococcus aureus with reduced susceptibility to mupirocin. Eur J Microbiol Infect Dis 15: 261-263.
16. Kretschmar M, Nichterlein T, Nebe CT, Hof H, Burger KJ (1996b) Fungicidal effect of tyrothricin on Candida albicans. Mycoses 39: 45-50.
17. Lammers TH, Dorner G (1951) Ärztl Wochenschr 6: 948. Cited from: Ruckdeschel et al. (1983).
18. Lind HE, Swanton EM (1954) Antibiot Chemother 4: 1161. Cited from: Ruckdeschel et al. (1983).
19. Matula C, Nahler G, Kreuzig F (1988) Salivary levels of gramicidin after use of tyrothricin-containing gargle/mouth-wash and Tyrothricin lozenges. Int J Clin Pharmacol Res 8: 259-261.
20. Muramatsu I, Sofuku S, Hagitani A (1972) A new synthetic and antibiotic analog of gramicidin S, (4-5 -aminovaleric acid)-gramicidin S. J Antibiot Tokyo 25: 189-190. Cited from: Kretschmar et al. (1995).
21. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds) (2003) Manual of clinical microbiology, ed 8, Washington DC (USA), ASM Press.
22. Ruckdeschel G, Beaufort F, Nahler G, Belzer O (1983) In vitro antibacterial activity of gramicidin and tyrothricin. Arzneimittelforschung 33: 1620-1622.
23. Schneider JJ, Unholzer A, Schaller M, Schäfer-Korting M, Korting HC (2005) Human defensins. J Mol Med 83: 587-595.
24. Scott MG, Hancock RE (2000) Cationic antimicrobial peptides and their multifunctional role in the immune system. Crit Rev Immunol 20: 407-431.
25. Seoh SA, Busath D (1993) The permeation properties of small organic cations in gramicidin A channels. Biophys J 64: 1017-1028.
26. Steinstraesser L, Koehler T, Jacobsen F, Daigeler A, Goertz O, Langer S, Kersting M, Steinau H, Eriksson E, Hirsch T (2008) Host defense peptides in wound healing. Mol Med 14: 528-537.
27. Wang G, Li X, Wang Z (2009) APD2: the updated antimicrobial Peptide Database and its application in peptide design. Nucleic Acids Res 37: 933-937.
28. Wang Z,Wang G (2004) APD: the Antimicrobial Peptide Database. Nucleic Acids Res 32: 590-592.
29. Voigt HU, Ehlers G (1989) Tyrothricin: Renaissance eines Lokalantibiotikums. Dt. Derm. 37: 647.
30. Willenberg W (1979) Zur Therapie akutentzündlicher Erkrankungen des Mund- und Rachenraumes. Zeitschr Allgemeinmed 55: 653-655. Cited from Kretschmar et al. (1995).